Results 71 to 80 of about 1,034,096 (317)

Colorectal Liver Metastasis: Can Cytokines Make the Difference?

open access: yes, 2023
Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide. Metastasis is the prime driver of CRC-related mortality, and the liver is the organ most frequently involved.
Gianluigi Giannelli   +2 more
core   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

open access: yesMolecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann   +61 more
wiley   +1 more source

Melanoma Metastasis [PDF]

open access: yesCancer Control, 1995
Cancer metastasis requires a series of sequential steps, each of which is rate limiting. Neoplasms are biologically heterogeneous, and the process of metastasis is highly selective. Multiple metastases often differ in biologic characteristics and can change during the course of the disease.
openaire   +2 more sources

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch   +13 more
wiley   +1 more source

Bacterial Involvement in Progression and Metastasis of Adenocarcinoma of the Stomach

open access: yes, 2022
Gastric cancer metastasis is a process in which the tumor microenvironment may carry significant influence. Helicobacter pylori (H. pylori) infection is well-established as a contributor to gastric carcinoma.
James M. Small   +9 more
core   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

open access: yesMolecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute   +4 more
wiley   +1 more source

URETERAL METASTASIS AS THE FIRST MANIFESTATION OF ASYMPTOMATIC GASTRIC CANCER [PDF]

open access: yes
Ureteral metastasis from gastric cancer is rare. It is usually diagnosed in the setting of an advanced gastric cancer or on postmortem examination. Isolated ureteral metastasis without involvement of other sites is extremely rare. We describe a 67-year-
ملک زاده, رضا   +2 more
core  

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Breast Cancer Associated Metastasis is Significantly Increased in a Model of Autoimmune Arthritis

open access: yes, 2008
Chronic inflammation is known to play a role in cancer initiation, promotion,and metastasis. However, the mechanism by which inflammation promotes metastasis is still unclear.
Latha Pathangey   +3 more
core  

Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab

open access: yes, 2022
SIMPLE SUMMARY: Denosumab, a bone-modifying agent, has been approved for the prevention of or reduction in skeletal-related events (SREs) in non-small cell lung cancer (NSCLC) patients with bone metastasis. However, the effect of denosumab on survival of
Yang, Cheng-Ta   +21 more
core   +1 more source

Home - About - Disclaimer - Privacy